<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00857025</url>
  </required_header>
  <id_info>
    <org_study_id>07243</org_study_id>
    <secondary_id>P30CA033572</secondary_id>
    <secondary_id>CHNMC-07243</secondary_id>
    <secondary_id>CDR0000634737</secondary_id>
    <nct_id>NCT00857025</nct_id>
  </id_info>
  <brief_title>Beta-Glucan in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase I Study of MM-10-001 In Advanced Non Small Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies, such as beta-glucan, may stimulate the immune system in&#xD;
      different ways and stop tumor cells from growing.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of beta-glucan in&#xD;
      treating patients with locally advanced or metastatic non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To assess the feasibility and toxicity of therapy with beta-glucan MM-10-001 in patients&#xD;
           with locally advanced or metastatic non-small cell lung cancer for which standard&#xD;
           curative or palliative measures do not exist or are no longer effective.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To explore analysis of the effect of beta-glucan MM-10-001 on the innate immune&#xD;
           compartment, in particular natural killer cell activation and effector status.&#xD;
&#xD;
        -  To perform correlatives (cytokine profiling) that will explore the effects of&#xD;
           beta-glucan MM-10-001 on the cytokine profile of these patients.&#xD;
&#xD;
        -  To document all clinical responses of these patients after treatment with beta-glucan&#xD;
           MM-10-001.&#xD;
&#xD;
        -  To explore potential beta-glucan MM-10-001 dose effects on the patient-reported&#xD;
           functional status.&#xD;
&#xD;
      OUTLINE: Patients receive oral beta-glucan MM-10-001 once or twice daily. Courses repeat&#xD;
      every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Blood samples are collected periodically for correlative studies. Samples are analyzed for&#xD;
      natural killer cell activation and effector status and cytokine profiling by flow cytometry.&#xD;
&#xD;
      Patient-reported functional status is assessed at baseline and periodically during treatment&#xD;
      by QOL-FACT-L questionnaire.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 21, 2008</start_date>
  <completion_date type="Actual">May 18, 2021</completion_date>
  <primary_completion_date type="Actual">November 24, 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>28 days after therapy begins</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum-tolerated dose</measure>
    <time_frame>28 days after therapy begins</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity as assessed by NCI CTCAE v3.0</measure>
    <time_frame>28 days after therapy begins</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Beta-glucan MM-10-001 activity as assessed by changes in natural killer cell activation and functional activity, cytokine profiling, and clinical benefit</measure>
    <time_frame>13 weeks after start of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported functional status</measure>
    <time_frame>13 weeks after start of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>1 year after start of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>1 year after start of study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (beta-glucan MM-10-001)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral beta-glucan MM-10-001 once or twice daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>beta-glucan MM-10-001</intervention_name>
    <description>Dose escalation with six patients treated at each of the following oral dosages: 2.5, 5.0, 7.5, 10, 15, 20, 30, 40, 50, and 80 mg/day</description>
    <arm_group_label>Treatment (beta-glucan MM-10-001)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
    <description>Performed on blood samples collected within 14 days prior to study treatment and at week 1, week 5, week 9, week 13 and every 4 weeks until the end of study treatment.</description>
    <arm_group_label>Treatment (beta-glucan MM-10-001)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Performed on blood samples collected within 14 days prior to study treatment and at week 1, week 5, week 9, week 13 and at the end of study treatment.</description>
    <arm_group_label>Treatment (beta-glucan MM-10-001)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
    <description>Assessment pre-study and week 5, week 9, week 13 and at off study.</description>
    <arm_group_label>Treatment (beta-glucan MM-10-001)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Pathologically confirmed non-small cell lung cancer&#xD;
&#xD;
               -  Locally advanced or metastatic disease for which standard curative or palliative&#xD;
                  measures do not exist or are no longer effective&#xD;
&#xD;
               -  Unresectable disease&#xD;
&#xD;
          -  No active or symptomatic brain metastases unless they were previously treated by&#xD;
             radiotherapy or surgery, stabilized, AND off steroid therapy for ≥ 4 weeks&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status (PS) 50-100% OR ECOG PS 0-2&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  WBC &gt; 2,000/mm³&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,000/mm³&#xD;
&#xD;
          -  Platelet count &gt; 50,000/mm³&#xD;
&#xD;
          -  Total bilirubin &lt; 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT &lt; 2.5 times ULN&#xD;
&#xD;
          -  Serum creatinine &lt; 2.5 mg/dL&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Must be able to swallow enteral medications (patients with feeding tubes are eligible)&#xD;
&#xD;
          -  No condition or disease that affects gastrointestinal (GI) function or impairs the&#xD;
             ability to take oral medications including any of the following:&#xD;
&#xD;
               -  GI tract disease&#xD;
&#xD;
               -  No intractable nausea or vomiting&#xD;
&#xD;
               -  Malabsorption syndrome&#xD;
&#xD;
               -  Requirement for IV alimentation&#xD;
&#xD;
               -  Prior surgical procedures effecting absorption&#xD;
&#xD;
               -  Uncontrolled inflammatory GI disease (e.g., Crohn disease, ulcerative colitis)&#xD;
&#xD;
          -  No concurrent condition requiring the use of systemic or topical steroids or the use&#xD;
             of immunosuppressive agents&#xD;
&#xD;
          -  No history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biological composition to beta-glucan MM-10-001&#xD;
&#xD;
          -  No uncontrolled concurrent illness including, but not limited to, any of the&#xD;
             following:&#xD;
&#xD;
               -  Ongoing or active infection&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Cardiac arrhythmia&#xD;
&#xD;
               -  Psychiatric illness or social situation that would limit compliance with study&#xD;
                  requirements&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)&#xD;
             or radiotherapy and recovered&#xD;
&#xD;
               -  Concurrent palliative radiotherapy for symptoms control allowed&#xD;
&#xD;
          -  At least 2 weeks since prior corticosteroids and no concurrent systemic or topical&#xD;
             steroids&#xD;
&#xD;
          -  At least 7 days since prior antioxidant supplements (vitamin C and E)&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
               -  Bisphosphonate therapy (e.g., pamidronate or zoledronate) allowed&#xD;
&#xD;
          -  No concurrent over-the-counter or dietary supplement containing beta-glucan (e.g.,&#xD;
             mushroom extracts, &quot;lentinan&quot; products, dried mushrooms) or other mushroom-derived&#xD;
             powders, liquids, capsules, gels, or any other dosage form&#xD;
&#xD;
          -  No concurrent use of immunosuppressive agents (e.g., cyclosporine and its analog)&#xD;
&#xD;
          -  No concurrent darbepoetin alfa or epoetin alfa&#xD;
&#xD;
          -  No concurrent colony-stimulating factors&#xD;
&#xD;
          -  No concurrent antiretroviral therapy for HIV-positive patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marianna Koczywas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 5, 2009</study_first_submitted>
  <study_first_submitted_qc>March 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2009</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

